Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
February 07, 2022 09:17 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3...
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
January 10, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration...
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
December 01, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
November 23, 2021 14:39 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 22, 2021 16:47 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
November 19, 2021 15:34 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Receives FDA Approval for ZIMHI
October 18, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
October 04, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s...
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
September 02, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral...
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
August 24, 2021 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting...